Details of the Drug Combinations

General Information of This Drug (ID: DMF30HL)

Drug Name

Zarnestra DMF30HL

Synonyms

JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 3	[1]
Chronic myelogenous leukaemia	2A20.0	Phase 2	[2]
Human papillomavirus infection	1A9Y	Phase 2	[2]
Myelodysplastic syndrome	2A37	Phase 2	[2]
Peripheral T-cell lymphoma	2A90.C	Phase 2	[2]
Colorectal cancer	2B91.Z	Phase 1/2	[3]
Pancreatic cancer	2C10	Phase 1/2	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Zarnestra + Mitomycin	DCZDUE6	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
Zarnestra + Idarubicin	DCWBFZH	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
Zarnestra + PF-562271	DCOGN22	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
Zarnestra + Ibrutinib	DCFS3BY	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[4]
------------------------------------------------------------------------------------

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Alpelisib + Zarnestra	DCPOZQT	Alpelisib	HNSCC	[5]
Etoposide + Zarnestra	DCGQ0SQ	Etoposide	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	[6]
Etoposide + Zarnestra	DCGWIHN	Etoposide	Adult Acute Megakaryoblastic Leukemia (M7)	[7]
Fulvestrant + Zarnestra	DC3JY46	Fulvestrant	Estrogen Receptor-positive Breast Cancer	[8]
Zarnestra + Capecitabine	DC40N2I	Capecitabine	Recurrent Breast Cancer	[9]
Zarnestra + Imatinib	DC74S8V	Imatinib	Leukemia, Myeloid, Chronic	[10]
Zarnestra + Temozolomide	DC8PBG7	Temozolomide	Glioblastoma Multiforme	[11]
Zarnestra + Bortezomib	DC94YG5	Bortezomib	Multiple Myeloma	[12]
Zarnestra + Bortezomib	DCI49ZU	Bortezomib	Refractory Multiple Myeloma	[13]
Zarnestra + Temozolomide	DCYW9AY	Temozolomide	Adult Giant Cell Glioblastoma	[14]
Zarnestra + Idarubicin	DC4RFMB	Idarubicin	Adult Acute Basophilic Leukemia	[15]
Zarnestra + Osimertinib	DCFBG6R	Osimertinib	NSCLC	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 12 DrugCom(s)

References

1	ClinicalTrials.gov (NCT00093990) Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	ClinicalTrials.gov (NCT04997902) Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
6	ClinicalTrials.gov (NCT00602771) Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
7	ClinicalTrials.gov (NCT00112853) Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
8	ClinicalTrials.gov (NCT00082810) Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
9	ClinicalTrials.gov (NCT00077363) Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
10	ClinicalTrials.gov (NCT00040105) Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
11	ClinicalTrials.gov (NCT00050986) Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
12	ClinicalTrials.gov (NCT00361088) A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
13	ClinicalTrials.gov (NCT00243035) Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
14	ClinicalTrials.gov (NCT00049387) Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
15	ClinicalTrials.gov (NCT00096122) Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
16	ClinicalTrials.gov (NCT05693090) Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer